3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization

Journal of Medicinal Chemistry

Volumn 48, Issue 8, 2005, Pages 2944-2956

  Pevarello, Paolo ^a   Brasca, Maria Gabriella ^a   Orsini, Paolo ^a   Traquandi, Gabriella ^a   Longo, Antonio ^a   Nesi, Marcella ^a   Orzi, Fabrizio ^a   Piutti, Claudia ^a   Sansonna, Pietro ^a   Varasi, Mario ^a   Cameron, Alexander ^a   Vulpetti, Anna ^a   Roletto, Fulvia ^a   Alzani, Rachele ^a   Ciomei, Marina ^a   Albanese, Clara ^a   Pastori, Wilma ^a   Marsiglio, Aurelio ^a   Pesenti, Enrico ^a   Fiorentini, Francesco ^b   Bischoff, Jim R ^a,c   Mercurio, Ciro ^a   more..

^a BU Oncology ^*  (Italy)

^b BU Preclinical Science   (Italy)

^c SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN A; CYCLIN B; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; GLYCOGEN SYNTHASE KINASE 3BETA; N (5 CYCLOPROPYL 1H PYRAZOL 3 YL) 2 [4 (2 OXO 1 PYRROLIDINYL)PHENYL]PROPANAMIDE; PHA 533533; PNU 292137; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL STRAIN CACO 2; CELL STRAIN HT29; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SOLUBILITY; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUDE MOUSE; PROCESS OPTIMIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD PROTEINS; CACO-2 CELLS; CDC2-CDC28 KINASES; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN A; CYCLIN-DEPENDENT KINASE 2; DRUG SCREENING ASSAYS, ANTITUMOR; HEPATOCYTES; HT29 CELLS; HUMANS; MICE; MICE, NUDE; MODELS, MOLECULAR; PERMEABILITY; PHOSPHORYLATION; PROTEIN BINDING; PYRAZOLES; PYRROLIDINONES; RATS; RETINOBLASTOMA PROTEIN; SOLUBILITY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS;

EID: 20944448138     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0408870     Document Type: Article

References (22)

1. The Molecular Basis of Cell Cycle and Growth Control; Stein, G. S., Baserga, R., Giordano, A., Denhardt, D. T., Eds.; John Wiley & Sons: New York, 1999.
2. (a) Fischer, P. M.; Endicott, J.; Meijer, L. Cyclin-dependent kinase inhibitors. Prog. Cell Res. 2003, 5, 235-248.
3. (b) Wang, S.; Meades, C.; Wood, G.; Osnowski, A.; Anderson, S.; Yuill, R.; Thomas, M.; Mezna, M.; Jackson, W.; Midgley, C.; Griffiths, G.; Fleming, I.; Green, S.; McNae, I.; Wu, S.-Y.; McInnes, C.; Zheleva, D.; Walkinshaw, M. D.; Fischer, P. M. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK Inhibitors: Synthesis, SAR Analysis, X-ray Crystallography, and Biological Activity. J. Med. Chem. 2004, 47 (7), 1662-1675.
4. (c) Hamdouchi, C.; Keyser, H.; Collins, E.; Jaramillo, C.; De Diego, J. E.; Spencer, C. D.; Dempsey, J. A.; Anderson, B. D.; Leggett, T.; Stamm, N. B.; Schultz, R. M.; Watkins, S. A.; Cocke, K.; Lemke, S.; Burke, T. F.; Beckmann, R. P.; Dixon, J. T.; Gurganus, T. M.; Rankl, N. B.; Houck, K. A.; Zhang, F.; Vieth, M.; Espinosa, J.; Timm, D. E.; Campbell, R. M.; Patel, B. K. R.; Brooks, H. B. The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines. Mol. Cancer Ther. 2004, 3 (1), 1-9.
5. Pevarello, P.; Brasca, M. G.; Amici, R.; Orsini, P.; Traquandi, G.; Corti, L.; Piutti, C.; Sansonna, P.; Villa, M.; Pierce, B. S.; Pulici, M.; Giordano, P.; Martina, K.; Fritzen, E. L.; Nugent, R. A.; Casale, E.; Cameron, A.; Ciomei, M.; Roletto, F.; Isacchi, A.; Fogliatto, G. Pesenti, E.; Pastori, W.; Marsiglio, A.; Leach, K. L.; Clare, P. M.; Fiorentini, F.; Varasi, M.; Vulpetti, A.; Warpehoski, M. A. 3-Aminopyrazole Inhibitors of CDK2/cyclin A as Anti-Tumor Agents: Lead Finding. J. Med. Chem. 2004, 47 (13), 3367-3380.
6. (a) Ohta, S.; Sano, A.; Yamashita, M.; Okamoto, M. Heterocycles 1993, 36 (4), 743-749.
7. (b) Lee, J. Y.; Baek, N. J.; Lee, S. J.; Park, H.; Lee, Y. S.; Heterocycles 2001, 55 (8), 1519-1526.
8. (c) Ryczek, J. Pol. J. Chem. 1996, 70 (12), 1518-1521.
9. Mantegani, S.; Arlandini, E.; Brambilla, E.; Cremonesi, P.; Varasi, M. Synth. Commun. 2000, 30 (19), 3543-3553.
10. (a) Snider, B. B.; Ahn, Y.; Foxman, B. M. Tetrahedron Lett. 1999, 40 (17), 3339-3342.
11. (b) Anjaneyulu, B.; Nagarajan, K. Indian J. Chem., Sect. B 1991, 30 (4), 399-406.
12. (c) Andres, J. I.; et al. Bioorg. Med. Chem. Lett 2002, 12 (4), 653-658.
13. (d) Wyckoff Chem Co. Inc. U.S. Patent 5,728,834 (98-206624), 1998.
14. (e) Tsuri, T.; Matsumoto, S.; et al. J. Med. Chem. 2000, 43 (10), 2040-2048.
15. (a) Wei, L. L.; Mulder, J. A.; Xiong, H.; Zificsak, C. A.; Douglas, C. J.; Hsung, R. P. Tetrahedron 2001, 57 (3), 459-466.
16. (b) Van Dort, M. E.; Jung, Y. W. Bioorg. Med. Chem. Lett. 2001, 11 (8), 1045-1047.
17. Pevarello, P.; Orsini, P.; Traquandi, G.; Varasi, M.; Fritzen, E. L.; Warpehoski, M. A.; Pierce, B. S.; Brasca, M. G. 3(5)-Acylaminopyrazole derivatives, process for their preparation and their use as antitumor agents. International Patent WO 01/12189, 2001.
18. Colombo, M.; Riccardi-Sirtori, F.; Rizzo, V. A Fully Automated Method for Accurate Mass Determination with High Performance Liquid Chromatography on a Quadrupole Orthogonal Acceleration Time-of-Flight Mass Spectrometer. Rapid Commun. Mass Sectrom. 2004, 18, 511-517.
19. Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation Mode. In Methods in Enzymology; Academic Press: New York, 1997; Vol. 276.
20. Brünger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; Grosse-Kunstleve, R. W. Crystallography and NMR System: A New Software Suite for Macromolecular Structure Determination. Acta Crystallog., Sect. D 1998, 54, 905-921.
21. Kleywegt, G. J.; Jones, T. A. Phi/psi-chology: Ramachandran revisited. Structure 1996, 4, 1395-1400.
22. McMartin, C.; Bohacek, R. S. QXP: Powerful, rapid computer algorithms for structure-based drug design. J. Comput.-Aided Mol. Des. 1997, 11, 333-344.